DFDA

Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R)

Treatment for Burkitt Lymphoma

Typical Dosage: Dose-adjusted based on nadir counts, intravenously

Effectiveness
85%
Safety Score
25%
Clinical Trials
3
Participants
3K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Dose-adjusted based on nadir counts, intravenously
Time to Effect
Within weeks of starting cycles
Treatment Duration
5-6 months (6-8 cycles)
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$70,000
Side Effect Mgmt:$70,000
Total Annual:$260,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$57,777/QALY
QALYs Gained
4.5
Outcome-Based Costs
Cost per Responder
$305,882.35
Cost per Remission
$346,666.67
Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R) Outcomes

for Burkitt Lymphoma

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Remission Rate
+75%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+90%
Febrile Neutropenia/Infection
+50%
Mucositis/Stomatitis
+55%
Nausea/Vomiting
+75%
Fatigue
+80%
Alopecia
+90%
Neurotoxicity (Vincristine-induced)
+30%
Cardiotoxicity (Doxorubicin-induced)
+7%

Sources:

cancer.gov
onclive.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R) in Burkitt Lymphoma

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500RECRUITINGPHASE2
View Study
30 participants
INTERVENTIONAL
Seattle, United States
Started: Mar 27, 2023

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

NCT06738368NOT YET RECRUITINGPHASE2
View Study
30 participants
INTERVENTIONAL
Seattle, United States
Started: Jan 1, 2026